Eli Lilly (LLY)
794.10
-104.85 (-11.66%)
NYSE · Last Trade: May 2nd, 12:22 AM EDT
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via Chartmill · May 1, 2025
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due to lower-than-expected profitability and full-year EPS guidance that missed significantly. On the other hand, Eli Lilly narrowly topped analysts' revenue expectations, fueled by surging demand for Mounjaro and Zepbound, which together drove a 45% year-over-year increase in total sales. Still, this was a softer quarter.
Via StockStory · May 1, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the S&P500 stocks with an unusual volume in today's session.
Via Chartmill · May 1, 2025
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · May 1, 2025
Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · May 1, 2025
Wall Street pushed higher in midday trading, with the S&P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully recovering the losses sustained after former President Donald Trump announced trade tariffs on April 2.
Via Benzinga · May 1, 2025
Get insights into the top gainers and losers in the S&P500 index of Thursday's pre-market session.
Via Chartmill · May 1, 2025
Eli Lilly cut its 2025 profit outlook after strong Q1 sales from Mounjaro and Zepbound and a $1.57 billion charge tied to a cancer drug acquisition.
Via Benzinga · May 1, 2025
The company cut its adjusted earnings per share guidance for the full year to $22.50 to $24.00, down from its previous forecast of $20.78 to $22.28.
Via Stocktwits · May 1, 2025
The drugmaker cut its profit guidance for the year, but kept its sales outlook.
Via Investor's Business Daily · May 1, 2025
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 45.2% year on year to $12.73 billion. The company expects the full year’s revenue to be around $59.5 billion, close to analysts’ estimates. Its non-GAAP profit of $3.34 per share was 3.4% below analysts’ consensus estimates.
Via StockStory · May 1, 2025
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year?
Via Investor's Business Daily · May 1, 2025
U.S. stock futures rose early Thursday morning, following the robust earnings of two "Mag 7" companies after markets closed on Wednesday.
Via Benzinga · May 1, 2025
Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance.
Via Stocktwits · May 1, 2025
Via Benzinga · May 1, 2025
Notwithstanding the recent seven-session run, the S&P 500 Index ended April — a historically strong month — with a loss of 0.8%.
Via Stocktwits · April 30, 2025
Eli Lilly, a pharmaceutical leader in obesity and diabetes treatment, is back in the spotlight, and for good reason.
Via Talk Markets · April 30, 2025
Eli Lilly reports 1Q earnings on Thursday, with EPS of $3.05 and revenues of $12.67 billion expected. Stock is up 14.35% in past year.
Via Benzinga · April 30, 2025